JP2017530130A - 腫瘍が誘発する自然免疫応答の免疫抑制を阻害する方法としてのアネキシンｖの使用 - Google Patents

腫瘍が誘発する自然免疫応答の免疫抑制を阻害する方法としてのアネキシンｖの使用 Download PDF

Info

Publication number
JP2017530130A
JP2017530130A JP2017516415A JP2017516415A JP2017530130A JP 2017530130 A JP2017530130 A JP 2017530130A JP 2017516415 A JP2017516415 A JP 2017516415A JP 2017516415 A JP2017516415 A JP 2017516415A JP 2017530130 A JP2017530130 A JP 2017530130A
Authority
JP
Japan
Prior art keywords
annexin
cancer
tumor
cells
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017516415A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017530130A5 (enExample
Inventor
フランシス・ジェラード・ブランケンバーグ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Leland Stanford Junior University
Original Assignee
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leland Stanford Junior University filed Critical Leland Stanford Junior University
Publication of JP2017530130A publication Critical patent/JP2017530130A/ja
Publication of JP2017530130A5 publication Critical patent/JP2017530130A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2017516415A 2014-10-03 2015-10-02 腫瘍が誘発する自然免疫応答の免疫抑制を阻害する方法としてのアネキシンｖの使用 Pending JP2017530130A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462059669P 2014-10-03 2014-10-03
US62/059,669 2014-10-03
PCT/US2015/053828 WO2016054574A1 (en) 2014-10-03 2015-10-02 Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response

Publications (2)

Publication Number Publication Date
JP2017530130A true JP2017530130A (ja) 2017-10-12
JP2017530130A5 JP2017530130A5 (enExample) 2018-11-01

Family

ID=55631651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017516415A Pending JP2017530130A (ja) 2014-10-03 2015-10-02 腫瘍が誘発する自然免疫応答の免疫抑制を阻害する方法としてのアネキシンｖの使用

Country Status (7)

Country Link
US (2) US11253568B2 (enExample)
EP (1) EP3200811A4 (enExample)
JP (1) JP2017530130A (enExample)
KR (1) KR20170063722A (enExample)
AU (1) AU2015327887A1 (enExample)
CA (1) CA2962255A1 (enExample)
WO (1) WO2016054574A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537210A (ja) * 2020-07-09 2023-08-31 中国科学院上海薬物研究所 Ｙｔｈｄｆ１を阻害するための組成物および方法

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10519504B2 (en) 2009-05-11 2019-12-31 Berg Llc Methods for treatment of oncological disorders using epimetabolic shifters, multidimensional intracellular molecules, or environmental influencers
KR101933732B1 (ko) 2011-04-04 2018-12-28 버그 엘엘씨 중추 신경 시스템 종양들의 치료 방법
CA2909094C (en) 2013-04-08 2023-06-27 Berg Llc Methods for the treatment of cancer using coenzyme q10 combination therapies
IL276423B2 (en) 2013-09-04 2024-05-01 Berg Llc Pharmaceutical preparations containing coenzyme Q10 for use in cancer treatment
EP3200811A4 (en) * 2014-10-03 2018-05-02 The Board of Trustees of The Leland Stanford Junior University Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response
WO2017087576A1 (en) 2015-11-16 2017-05-26 Berg Llc Methods of treatment of temozolomide-resistant glioma using coenzyme q10
WO2018018018A1 (en) * 2016-07-21 2018-01-25 Berg Llc Methods for the treatment of cancer using coenzyme q10 in combination with immune checkpoint modulators
US10874711B2 (en) 2017-07-05 2020-12-29 The Board Of Trustees Of The Leland Stanford Junior University Use of annexin V to reduce the spread of intracellular pathogens
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US20240293505A1 (en) * 2021-03-29 2024-09-05 The Board Of Trustees Of The Leland Stanford Junior University Reversal of ctl exhaustion with annexin v
US20250049884A1 (en) * 2022-01-03 2025-02-13 The Board Of Trustees Of The Leland Stanford Junior University Blocking and reversing extracellular vesicle driven transcriptomic transformation with annexin v treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096467A1 (en) * 1995-11-06 2004-05-20 Kalden Joachim Robert Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites
US20060293226A1 (en) * 2003-01-21 2006-12-28 Wolf Bertling Medicament and use thereof for tumor therapy

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6818213B1 (en) * 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
US7635680B2 (en) * 2001-02-21 2009-12-22 Alavita Pharmaceuticals, Inc. Attenuation of reperfusion injury
JP2004529922A (ja) * 2001-04-03 2004-09-30 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ 生体内における細胞死の画像化の方法
DE10145254A1 (de) 2001-09-13 2003-04-10 November Ag Molekulare Medizin Verwendung eines Proteins zur Herstellung eines Medikaments zur Stimulierung einer inflammatorischen zellulären Immunantwort
US8071545B2 (en) * 2005-03-15 2011-12-06 Lewis S. Coleman, Md, Inc. Therapies and compositions for controlling the stress mechanism and for stabilizing hemostasis in an organism
GB0911042D0 (en) * 2009-06-25 2009-08-12 Istituto Superiore Di Sanito Treatment of tumorigenic cells in solid tumours
EP3200811A4 (en) * 2014-10-03 2018-05-02 The Board of Trustees of The Leland Stanford Junior University Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096467A1 (en) * 1995-11-06 2004-05-20 Kalden Joachim Robert Drug, in particular for modulating the immunological response for the control of viruses, tumors, bacteria and parasites
US20060293226A1 (en) * 2003-01-21 2006-12-28 Wolf Bertling Medicament and use thereof for tumor therapy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CALLAHAN MK, WOLCHOK JD: "At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy", JOURNAL OF LEUKOCYTE BIOLOGY, vol. 94, no. 1, JPN6019018980, July 2013 (2013-07-01), pages 41 - 53, ISSN: 0004216628 *
YAN X ET AL.: "Annexin-V promotes anti-tumor immunity and inhibits neuroblastoma growth in vivo", CANCER IMMUNOLOGY, IMMUNOTHERAPY, vol. 61, no. 11, JPN6019018978, 2012, pages 1917 - 1927, ISSN: 0004216627 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023537210A (ja) * 2020-07-09 2023-08-31 中国科学院上海薬物研究所 Ｙｔｈｄｆ１を阻害するための組成物および方法

Also Published As

Publication number Publication date
WO2016054574A1 (en) 2016-04-07
CA2962255A1 (en) 2016-04-07
US20170202914A1 (en) 2017-07-20
EP3200811A1 (en) 2017-08-09
AU2015327887A1 (en) 2017-04-13
KR20170063722A (ko) 2017-06-08
US11253568B2 (en) 2022-02-22
US20220160829A1 (en) 2022-05-26
EP3200811A4 (en) 2018-05-02

Similar Documents

Publication Publication Date Title
US20220160829A1 (en) Use of annexin v as a method to block tumor induced immunosuppression of the innate immune response
Parvez et al. PD-1 and PD-L1: architects of immune symphony and immunotherapy breakthroughs in cancer treatment
ES2927305T3 (es) Régimen contra el cáncer usando anticuerpos anti-CD47 y anti-CD20
JP2022535972A (ja) がん免疫療法の皮下投与のための組成物及び方法
JP2023002792A (ja) ソマトスタチン受容体を過剰発現する神経内分泌腫瘍を処置する方法
ES2932286T3 (es) Terapia contra el cáncer de ovarios basada en agente anti-CD47
US20150273033A1 (en) Combinations of checkpoint inhibitors and therapeutics to treat cancer
JP7769032B2 (ja) 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
ES2978486T3 (es) Métodos para promover la respuesta de linfocitos T
JP2022527081A (ja) 血液がんおよび固形がんの治療のためのキメラ抗原受容体改変ｔ細胞（ｃａｒ－ｔ）
JP2021524449A (ja) 分子アジュバント
WO2022102695A1 (ja) 抗ｂ７－ｈ３抗体－薬物コンジュゲート投与による中皮腫の治療
CN116744976A (zh) 用于治疗实体癌的her3放射免疫疗法
JP2015518835A (ja) 癌幹細胞を標的とした癌ワクチン
KR102606179B1 (ko) 암의 치료를 위한 abx196을 포함하는 조합물
US20250049884A1 (en) Blocking and reversing extracellular vesicle driven transcriptomic transformation with annexin v treatment
JP2025518126A (ja) がんの治療のための同種異系低免疫生体模倣型ナノ小胞
Busato Glypican 1-targeted therapeutic approaches adopting doxorubicin-loaded chitosan nanobubbles and antibody-based strategy in the context of Pancreatic Ductal Adenocarcinoma
US20220047701A1 (en) Combination of her2/neu antibody with heme for treating cancer
US20230255978A1 (en) Methods for treating glioblastoma
WO2025089339A1 (ja) がんの治療剤
WO2023203561A1 (en) Apoptotic cell - check point inhibitor combination therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180921

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190528

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190828

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200225